Study of the Effectiveness and Safety of Ocrelizumab in Adults with Early Stage Relapsing Remitting Multiple Sclerosis

What we are studying

The purpose of this study is to see if Ocrelizumab (study drug) will halt the worsening of the signs and symptoms of early stage MS.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 55

Eligibility Criteria

  • Have a definite diagnosis of Relapsing Remitting Multiple Sclerosis
  • Have a length of disease duration of less than or equal to 3 years
  • Had one or more clinical relapses within the last 12 months

What is involved

  • Visits to the Neurology Outpatient Clinic for assessments in addition to 9 visits to the CRU for study drug administration
  • Neurological Exams
  • Questionnaires
  • Telephone visits
  • MRI


You will be paid $1200.00 if you complete all the scheduled study visits. If you withdraw for any reason from the study before completion you will be paid $100.00 for each complete study visit.

Contact Information

Study Coordinator
Janet Hutchens
[email protected]

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.